JPMorgan lowered the firm’s price target on Fresenius Medical to EUR 28 from EUR 32.10 and keeps an Underweight rating on the shares.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on FMS:
- Fresenius Medical Care continues to execute on turnaround plan and raises 2023 earnings outlook due to strong operational performance in first nine months and solid business outlook for the fourth quarter
- FMS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Fresenius Medical price target lowered to EUR 32.10 from EUR 38 at JPMorgan
- Fresenius Medical price target lowered to EUR 38 at Morgan Stanley
- Fresenius: GLP-1s slow CKD progression, mortality would decline, Reuters says